Treats hyperkalemia. ANDA 204071, held by Nuvo Pharms Inc. Sodium Polystyrene Sulfonate.
As of Nov 16, 2026, ANDA 204071 (Sodium Polystyrene Sulfonate), held by Nuvo Pharms Inc, was first approved by FDA on Nov 28, 2014, with 1 approved supplement and 0 published complete response letters.
Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. Limitation of Use: Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 28, 2014 | Original application | Approved | None posted |
| Sodium Polystyrene Sulfonate454GM/BOT · powder;oral, rectal | Sodium Polystyrene Sulfonate | Rx |
| Sodium Polystyrene Sulfonate15GM/BOT · powder;oral, rectal | Sodium Polystyrene Sulfonate | Rx |
| Feb 21, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 28, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters